FDA approves Tzield (teplizumab-mzwv) to delay the onset of stage 3 type 1 diabetes in young children – Sanofi
The FDA has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years and older to as young as one year of age… read more.
